Innovative Wearable and Open Platform for a Personalized Treatment of Stress

Projektinformationen

XANA

ID Finanzhilfevereinbarung: 781703

DOI

10.3030/781703

Projekt abgeschlossen

EK-Unterschriftsdatum 17 Juli 2017

Startdatum 1 August 2017

Enddatum 30 November 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

WALDEN MEDICAL NEURO DIGITAL THERAPIES, S.L.
Spain

Periodic Reporting for period 1 - XANA (Innovative Wearable and Open Platform for a Personalized Treatment of Stress)

Berichtszeitraum: 2017-08-01 bis 2017-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Walden Medical® has been created aiming to design, develop and commercialize XANA product (device and platform): a personalized and non-invasive neurostimulation treatment for stress relief. Previous R&D project results, where three of the founders were involved, showed the potential and technical viability required for boosting the creation of the company.
The initial goal was to develop a non-invasive system to stimulate parasympathetic nervous system activity and thus maintain homeostasis, compensating for the excessive activation of the sympathetic nervous system due to the response to stressful stimuli.
After several anatomical and physiological studies, we designed an ergonomic and usable wearable neurostimulator operated from a software app for smartphone and capable of electrically stimulating the Auricular Brach of the Vagus Nerve.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Once the design was completed, we developed the prototype for a Minimum Viable Product (MVP) that consists of an auricular electrical neurostimulator connected by Bluetooth to our software app.
This development process served also to determine the functional properties and specifications for the optimization of the XANA MVP product. The improvements to get a more user-friendly, efficient and customized product (XANA BCAS) are:
Bilateral: one stimulator for each ear, to improve efficiency.
Customized: An scan of the user´s auditory canals will be used to build the anatomically customized stimulators.
Autonomous: the stimulators can operate without the smartphone.
SMART: implementation of both electrical and mechanical stimulation and music therapy.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Since stress affects over 40% of the worldwide population and is linked to over 70% of physical and mental disorders XANA will help to:
1. Solve a high prevalence problem associated to current lifestyle.
2. Prevent other conditions that can be triggered by stress (e.g. anxiety, depression).
3. Decrease the costs of absenteeism and reduce the enormous healthcare system costs, directly caused by stress and indirectly caused by stress-linked-conditions.
4. Reduce the abuse of medication (Benzodiazepines) that causes addiction among other serious side-effects.
5. Develop the mobile Health offer which is the main social trend regarding prevention, monitoring and treatment in the health sector.

xana.png

walden.png